- Capturing the global 파라오 슬롯 with next-generation filler powered by the ‘MIRACLE method’
- Anticipating synergy with overseas ventures in China, Brazil, Mongolia, Laos, and the Philippines
[by Kang, In Hyo] DongKoo Bio&파라오 슬롯 announced on March 17 that it has become the largest shareholder of Arum Medics after signing a new stock acquisition agreement. This strategic move aims to strengthen its presence in the beauty and plastic surgery market. By leveraging its established sales network, DongKoo Bio&파라오 슬롯 intends to actively participate in Arum Medics’ management and accelerate the expansion of its beauty and plastic surgery business.
Arum Medics is recognized as a leading company in Korea, distinguished by its expertise in filler development and proprietary platform technology. Notably, the company employs the differentiated ‘MIRACLE method’ in its filler manufacturing process. According to DongKoo Bio&파라오 슬롯, the MIRACLE (Most Improved Reaction for Augmentation of Cross Linking Efficiency) method represents a next-generation filler manufacturing technology that addresses the limitations of first-generation fillers. This platform technology enables the production of dual-phasic fillers with high elasticity and strong cohesion.
This technology has successfully secured patent registration in Korea, and by precisely regulating key crosslinking parameters of the filler (temperature, concentration, duration, crosslinking agent, and more), it optimizes wrinkle correction efficacy while enhancing procedural convenience. The company further stated that this approach enables the production of filler products with superior elasticity and cohesion compared to Korean and international competitors, and it is regarded as a key technology poised to drive the next-generation filler 파라오 슬롯.
The filler market is shifting from purely cosmetic applications to innovative therapeutic solutions that integrate advanced regenerative medical technologies. DongKoo Bio&파라오 슬롯 is actively engaged in the development of cell therapy and high-performance cosmeceutical products that incorporate immune cell technology through a memorandum of understanding (MOU) with ImmunisBio. The company aims to strengthen its competitive position in the premium filler market by collaborating with Arum Medics. This strategy focuses on positioning DongKoo Bio&파라오 슬롯 as a leading global brand, leveraging technological prowess and differentiation in the beauty and plastic surgery market by introducing premium fillers that incorporate advanced regenerative medical technology, setting it apart from the conventional filler market.
Dongkoo Bio&파라오 슬롯 aims to actively pursue the global beauty and plastic surgery market by maximizing synergies with its existing international operations in China, Brazil, Mongolia, Laos, and the Philippines. In Mongolia, the company has established ‘Dongkoo Bio&파라오 슬롯 Co., LLC’ in partnership with One All Gate, where it is currently running a medical service consulting and wholesale consulting business.
In Laos, DongKoo Bio&파라오 슬롯 is building a distribution network for emergency medicines in 파라오 슬롯cies and convenience stores through its local joint venture, ‘LDK 파라오 슬롯 Factory Co., Ltd.’ Meanwhile, in the Philippines, the company is engaged in a hospital franchise business as well as cosmetics and filler operations in collaboration with ‘Adization,’ a Philippine healthcare group.
Additionally, DongKoo Bio&파라오 슬롯 is promoting the global expansion of its beauty and plastic surgery business, including cell therapy, cosmetics, and fillers, through strategic partnerships. In Brazil, it is collaborating with ‘MedBeauty,’ a 파라오 슬롯ceutical distribution company in Brazil, while in China, the company is working with the Lancy Group, which operates more than 70 aesthetic, plastic surgery, and dermatology clinics.
The global beauty and plastic surgery 파라오 슬롯 has experienced rapid growth in recent years. According to a report by Astute Analytica, the global 파라오 슬롯 size for aesthetic and plastic surgery is projected to be USD 75.6 billion in 2023 and is expected to grow to USD 212.5 billion by 2032.
In response to the rapid growth of the market, DongKoo Bio&파라오 슬롯 plans to expand its filler and regenerative medicine solutions to the global market with differentiated technologies. The company aims to capitalize on its position as the ‘No. 1 dermatology prescription company.’
“Through our collaboration with Arum Medics, we intend to introduce innovative products in the filler and regenerative medicine sectors,” said Cho Yong-joon, CEO of DongKoo Bio&파라오 슬롯. “We aim to create synergies with our ongoing global business initiatives and evolve into a brand with strong global competitiveness,” he added.